CGRP Receptor Antagonists and 5-HT1F Receptor Agonist in the Treatment of Migraine

被引：17
|
作者：
Capi, Matilde [1 ]
De Angelis, Valerio [2 ]
De Bernardini, Donatella [1 ]
De Luca, Ottavia [3 ]
Cipolla, Fabiola [2 ]
Lionetto, Luana [1 ]
Simmaco, Maurizio [1 ,3 ,4 ]
Martelletti, Paolo [2 ]
机构：
[1] St Andrea Univ Hosp, Mass Spectrometry Unit, Lab Clin Biochem, I-00185 Rome, Italy
[2] Sapienza Univ Rome, Dept Clin & Mol Med, I-00185 Rome, Italy
[3] St Andrea Univ Hosp, Adv Mol Diagnost Unit, Lab Clin Biochem, I-00185 Rome, Italy
[4] Sapienza Univ, Dept Neurosci Mental Hlth & Sensory Organs NESMOS, I-00185 Rome, Italy
来源：
JOURNAL OF CLINICAL MEDICINE | 2021年 / 10卷 / 07期
关键词：
migraine; CGRP; therapy; gepants; ditans; antagonism; CGRP receptor; GENE-RELATED PEPTIDE; MONOCLONAL-ANTIBODIES; SAFETY PROFILE; LASMIDITAN;
D O I：
10.3390/jcm10071429
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Discovering that calcitonin-related peptide (CGRP) plays a key role in the complex pathophysiology of migraine has allowed us to make great strides in the development of new approaches for acute and preventive treatment. This evidence has led to the development of small molecules antagonist molecules of the CGRP receptor ("gepants") and of a new class of medications called "Ditans". This review presents the data from clinical trials reporting the efficacy, safety, and tolerability of the new drugs used in the treatment of migraines. Evidences show that therapeutic approaches targeted to CGRP have the potential to transform the clinical management of migraine, even though its appropriate place has yet to be determined with accuracy.
引用
收藏
页数：17
相关论文
共 50 条
  • [31] New Agents for Acute Treatment of Migraine: CGRP Receptor Antagonists, iNOS Inhibitors
    Jan Hoffmann
    Peter J. Goadsby
    Current Treatment Options in Neurology, 2012, 14 : 50 - 59
  • [32] THE DEVELOPMENT OF A HIGHLY SELECTIVE 5-HT(1) RECEPTOR AGONIST, SUMATRIPTAN, FOR THE TREATMENT OF MIGRAINE
    FENIUK, W
    HUMPHREY, PPA
    DRUG DEVELOPMENT RESEARCH, 1992, 26 (03) : 235 - 240
  • [33] Targeting the 5-HT1B/1D and 5-HT1F receptors for acute migraine treatment
    Huang, Pin-Chung
    Yang, Fu-Chi
    Chang, Ching-Mao
    Yang, Chun-Pai
    UPDATE ON EMERGING TREATMENTS FOR MIGRAINE, 2020, 255 : 99 - 121
  • [34] Colocalization of 5-HT1F receptor and glutamate in neurons of the vestibular nuclei in rats
    Ahn, Seong-Ki
    Khalmuratova, Roza
    Jeon, Sea-Yuong
    Kim, Jin-Pyeong
    Park, Jung-Je
    Hur, Dong-Gu
    Kim, Dae-Woo
    Balaban, Carey D.
    NEUROREPORT, 2009, 20 (02) : 111 - 115
  • [35] CGRP Receptor Antagonism and Migraine
    Edvinsson, Lars
    Ho, Tony W.
    NEUROTHERAPEUTICS, 2010, 7 (02) : 164 - 175
  • [36] Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy?
    Rubio-Beltran, Eloisa
    Labastida-Ramirez, Alejandro
    Villalon, Carlos M.
    MaassenVanDenBrink, Antoinette
    PHARMACOLOGY & THERAPEUTICS, 2018, 186 : 88 - 97
  • [37] NXN-188, a selective nNOS inhibitor and a 5-HT1B/1D receptor agonist, inhibits CGRP release in preclinical migraine models
    Bhatt, Deepak K.
    Gupta, Saurabh
    Jansen-Olesen, Inger
    Andrews, John S.
    Olesen, Jes
    CEPHALALGIA, 2013, 33 (02) : 87 - 100
  • [38] Clinical and preclinical rationale for CGRP-receptor antagonists in the treatment of migraine
    Tepper, Stewart J.
    Stillman, Mark J.
    HEADACHE, 2008, 48 (08): : 1259 - 1268
  • [39] 5-HT3 RECEPTOR ANTAGONISTS AND MIGRAINE THERAPY
    FERRARI, MD
    JOURNAL OF NEUROLOGY, 1991, 238 : S53 - S56
  • [40] Real world considerations for newly approved CGRP receptor antagonists in migraine care
    Scuteri, Damiana
    Tonin, Paolo
    Nicotera, Pierluigi
    Bagetta, Giacinto
    Corasaniti, Maria Tiziana
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2022, 22 (03) : 221 - 230
12345